WO1999064071A1 - Procede de preparation d'un immunoadsorbant adn dans une resine carbonisee - Google Patents
Procede de preparation d'un immunoadsorbant adn dans une resine carbonisee Download PDFInfo
- Publication number
- WO1999064071A1 WO1999064071A1 PCT/CN1999/000076 CN9900076W WO9964071A1 WO 1999064071 A1 WO1999064071 A1 WO 1999064071A1 CN 9900076 W CN9900076 W CN 9900076W WO 9964071 A1 WO9964071 A1 WO 9964071A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- resin
- carbonized resin
- immunoadsorbent
- hours
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
Definitions
- the invention relates to a medical adsorbent material, and particularly to an immunoadsorbent.
- This adsorbent immobilizes the active substance DNA on a carbonized resin as a carrier material and becomes a DNA immunoadsorbent, which can be used for hemoperfusion therapy for systemic benign erythema. Background technique
- SLE Systemic lupus erythematosus
- DNA immunosorbents for hemoperfusion of patients is a new type of therapy developed in the past decade. This method is described in detail in European Patent EP 0 272 792 A1 (1987) by Jnes, Frank R, the entire contents of which are incorporated herein by reference.
- DNA immunoadsorbent hemoperfusion therapy relies on the specific recognition of anti-DNA antibodies of pathogenic substances by DNA to remove the pathogenic substances from the patient's blood to relieve the disease and improve the immune function of the patient, so that the patient gradually recovers to health. The therapeutic effect of this kind of therapy is remarkable, and it is being paid more and more attention by the clinical medical community.
- the coating conditions need to be improved to improve the adsorption performance of the adsorbent.
- the current carbonized resin is expensive, and it is necessary to improve the manufacturing process of the carbonized resin in order to reduce the cost and help promote the clinical application of the immunosorbent.
- the object of the present invention is to provide an improved method for preparing a carbonized resin DNA immunoadsorbent. This method improves DNA coated envelope strips fixed with carbonized resin envelope method
- Replacement page Components, which improves the adsorption performance of the adsorbent, and eliminates and eliminates heat sources during the preparation process, making it more in line with clinical medical requirements. In addition, this method also greatly reduces the manufacturing cost of the adsorbent.
- the method for preparing the DNA immunoadsorbent of the present invention uses a carbonized resin as a carrier, and an effective amount of DNA is immobilized thereon, and the content of the DNA is 0.3-0.5nig / ml of resin.
- the method includes the following steps:
- Styrene and propionitrile are used as monomers
- diethylpyrene is used as a cross-linking agent
- trioxane monomer and cross-linking agent weight ratio
- Benzoyl is used as an initiator
- a 2% polyvinyl alcohol aqueous solution is used as a dispersion medium to perform suspension polymerization, and the reaction is performed at a temperature of 8 ° C for 5 hours; then, the ammonium is distilled at a temperature of 96 t, and then at a temperature of 100 ° C.
- the spheres are polymerized and boiled for 2-3 hours to further polymerize and harden; then, wash with hot water, bake at 50 C, and then elute the wax with petroleum ether to obtain a ternary copolymerized super macroporous resin;
- the content of DNA in the DNA immunoadsorbent prepared by the method of the present invention reaches 0.3-0.5 mg / mi resin.
- the DNA immunoadsorbent prepared according to the present invention is packed into a special adsorption tank and sterilized into a medical blood perfusion adsorption device.
- the blood is drawn from the patient's arteries and flows through the adsorption device.
- the pathogenic substances in the patient's blood are adsorbed by the DNA immunosorbent.
- the clean blood flows out of the device and flows back to the patient through the vein.
- Perfusion treatment usually takes 2-3 hours. Hemoperfusion is similar to hemodialysis, safe, easy, and costly.
- Replacement page (by-law 26 ⁇ ) Stir, warm to 80 ° (:, react for 3-5 hours. Raise the temperature of the water bath to 90-100 e C, steam the garnet. Boil the sphere polymer at 100 ° C for 2 hours, filter, and use hot distilled water Wash the resin several times. Dry at 50 * C, rinse with petroleum ether or extract with heat to remove the porogen liquid paraffin to obtain a ternary copolymerized super macroporous resin. Use a standard sieve to select a 0.45-1.0mm qualified resin.
- the obtained carbonized resin was boiled with 2 volumes of 5% hydrochloric acid for 30 minutes, and then ice-washed with double distillation to neutrality. Boil with twice the volume of 5% sodium hydroxide for 30 minutes and rinse with neutral distilled water. 50t baking thousand. Extract with hot absolute ethanol for 24 hours, 'Hong Qian spare.
- the carbonized resin DNA immunoadsorbent prepared in the present invention was packed in a 250 ml adsorption tank, sealed and sterilized, soaked in sterile physiological saline for more than 30 minutes before use, and then rinsed with 3000 ml of sterile physiological saline.
- the femoral artery and brachial vein were inserted into the patient. Heparin was intravenously injected at a dose of 1-1.5 mg / kg body weight 10-20 minutes before perfusion.
- the entire perfusion system was insulated at 37 ° (: perfusion was started after the arteriovenous was connected, and the flow rate gradually increased from 50ml / min to ⁇ to 200ml / nim. Blood was collected from the arterial end, and DNA antibodies, immune complexes, and other biochemical indicators were measured.
- the invention adopts a new process synthesis method to synthesize a carbonized resin with excellent performance as an adsorbent carrier material.
- an ultra-large amount of porogen is used (the amount of porogen is three times the total amount of the monomer and the cross-linking agent).
- the amount of the agent and the rate of temperature increase, that is, the polymerization rate is strictly controlled.
- the porogen is rapidly distilled off, so that a resin with ultra-large pores and a large specific surface area can be finally obtained.
- the calcination, programmed temperature, carbonization temperature and water vapor activation of the carbonization process are very important, which directly affect and determine the yield and structural properties of the carbonized resin.
- the carbonized resin prepared by the present invention has suitable pore size and specific surface area (pore size 20-35A) (Specific surface area 800-1200n ⁇ ml), is an excellent carrier material for the preparation of DNA immunoadsorbents, has very good blood compatibility, and has a low destruction rate on platelets, red blood cells and white blood cells. It has also been proved by clinical application.
- the superior properties of the carbonized resin of the present invention has also been proved by clinical application.
- the carbonized resin DNA immunoadsorbent prepared by the present invention has been used in more than 150 clinical applications in 28 hospitals in 17 cities across the country, with an effective rate of 98%.
- the patient not only prolongs life, but also restores health and labor capacity.
- Tables 1 and 2 list some SLE clinical reports, respectively.
- the concentration of the anti-ds-DNA antibody of the pathogenic substance in the blood was significantly reduced after blood perfusion of ten patients, and the urine protein, erythrocyte sedimentation rate, and anti-nuclear antibody titer were significantly improved. Except for one death (38 months of survival), the remaining 9 people have survived for more than 32 months, and their ability to live and work has been restored.
- the sphere polymer was boiled at 100 ° C for 2 hours to further polymerize and harden, filtered, washed with hot steam and hydrophobic water several times to remove the polyvinyl alcohol. Bake at 50 C, rinse the resin with petroleum ether (60-90, remove the liquid stone bee from the porogen. Use a standard sieve to screen qualified resin in the range of 0.45-1.0 mm, about 400 ml.
- the carbonization temperature in the tubular resistance furnace was changed to 580 ° C, which resulted in a specific surface area of the obtained carbonized resin of only 100 m / g. about.
- the remaining steps are the same as in Example 1. It can be seen from the change of this parameter that the content of DNA in the finished adsorbent will be greatly reduced.
- Example 1 In the process of preparing the carbonized resin in Example 1, the water vapor activation time in the process of preparing the carbonized resin was changed to 0.5 hours. As a result, the specific surface area of the obtained carbonized resin was slightly reduced, and was 800-1000 m 2 / g. The remaining steps are the same as in Example 1. It can be inferred that the DNA content in the finished adsorbent will also be reduced accordingly.
- Example 1 In the process of preparing the carbonized resin in Example 1, after adding the resin to the tubular resistance furnace, the temperature was directly increased to 800 t under the protection of carbon dioxide without the step of pre-firing at 200 ° C for 10 hours. Caking, carbonization The yield of the resin is very low, and only the carbonized resin of less than 200ml is obtained with the same amount of feed. It can be seen that the pre-firing step can greatly improve the yield of the product.
- the feeding amount of the calf thymus DNA solution was changed to 87.5 ml, the feeding amount of the collodion solution was changed to 100 ml, and the feeding of the carbonized resin was changed.
- the volume was changed to 250ml.
- the remaining conditions are the same as in Example 1.
- the DNA content in the finished adsorbent was increased to 0.42 mg / ml resin.
- the method for preparing a carbonized resin DNA immunoadsorbent according to the present invention improves the carbon coating of the carbonized resin coating to fix DNA, improves the adsorption performance of the adsorbent, and avoids and replaces pages during the preparation process (Article 26 of the Detailed Rules). Eliminates the heat source material, so that it can be made into a DNA immunoadsorbent with higher adsorption efficiency and more in line with clinical medical requirements.
- the method of the present invention is easy to obtain from rhenium raw materials, the process is reasonable, and the manufacturing cost of the adsorbent can be greatly reduced.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rehabilitation Therapy (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Carbon And Carbon Compounds (AREA)
Description
碳化树脂 DNA免疫吸附剂的制备方法 技术领域
本发明涉及医用吸附材料, 特别表涉及一种免疫吸附剂。 这种吸附剂将 活性物质 DNA固定在作为载体材料 '的碳化树脂上, 成为 DNA免疫吸附剂, 可用于治疗系统性红斑良疮的血液灌流疗法。 背景技术
系统性红斑狼疮 (简称 SLE ) 是一种自身免疫性缺陷的疑难病症, 临床 上尚无有效疗法。 SLE 的病因不详, 患者往往因全身重要器官的功能衰竭而 死亡, 死亡率较高。
使用 DNA 免疫吸附剂对患者进行血液灌流, 是近十几年来发展起来的 新型疗法。 Jnes, Frank R的欧洲专利 EP 0 272 792 A1 ( 1987 ) 对这种方法作 了详细说明, 该专利文献的全部内容作为本申请的参考。 DNA 免疫吸附剂 血液灌流疗法是依靠 DNA对致病物质抗 DNA抗体的特异识别作用, 清除患 者血液中的致病物质, 以緩解病情, 改善患者的免疫功能, 从而使患者逐渐 恢复健康。 这种疗法疗效显著, 正日益受到临床医学界的重视。
美国的 Tennan DS等首次使用活性炭为载体材料, 采用火棉胶包膜固定 DNA, 将制得的 DNA免疫吸附剂用血液灌流法治疗了一名重度 SLE患者, 使患者生命延长了 31 天 [Lancet,1979,2(8147):S24-7],开辟了用免疫吸附剂治 疗 SLE的新纪元。 但是, Terman的吸附剂由于使用活性炭作载体, 机械强度 和耐磨性较差, 微小颗粒容易脱落, 会使毛细血管堵塞。
杨彦等人研究开发了采用日本碳化树脂为载体的吸附剂, 这种吸附剂用 火棉胶包膜固定 DNA, DNA 预先用氯化四氮唑兰 (BT ) 络合 [中国生物医 学工程学报, 1985, 4 ( 2 ) : 88-95; 高等学校化学学报, 1985 , 6 ( 9 ) : 843-847】。 所得到的 DNA免疫吸附剂的机械强度大大提高了, 而且, DNA不脱落。 这 种吸附剂已经在中国成功地应用于临床治疗 SLE, 疗效显著。 但是, 临床应 用中发现, 病人存在寒颤现象, 说明吸附剂中存在热源物质。 另外, 有待改 进包膜条件, 以提高吸附剂的吸附性能。 此外, 目前的碳化树脂价格昂贵, 有必要改进碳化树脂的制造工艺, 以便降低成本, 有利于推广免疫吸附剂的 临床应用。 发明内容
由于载体材料的结构性能以及与血液的相容性直接影响 DNA 免疫吸附 剂的使用性能, 因此, 本发明的目的是提供一种改进的碳化树脂 DNA 免疫 吸附剂的制备方法, 这种方法改进了用碳化树脂包膜法固定 DNA 的包膜条
― 1 ―
替换页 (细则第 26条)
件, 提高了吸附剂的吸附性能, 并且在制备过程中遊免和消除了热源物质, 使其更加符合临床医用要求。 此外, 这种方法还大大降低了吸附 '剂的制造成 本。
本发明的 DNA 免疫吸附剂的制备方法使用碳化树脂作为载体, 在其上 固定了有效量的 DNA, DNA的含量为 0.3-0.5nig/ml树脂, 其特正在于, 该 方法包括下列步骤:
( 1 ) 制备碳化树月旨
以苯乙烯和丙埗腈为单体, 以二乙燫笨为交联剂, 以三倍亍单体和交联 剂 (重量比) 的曱笨和液体石蜡为致孔剂, 以过氣化笨曱酰为引发剂, 以 2%聚乙烯醇水溶液为分散介质, 进行悬浮聚合, 在 8(TC 溫度下反应 5小时; 然后, 在 96 t温度下蒸馏曱笨, 再在 100 °C温度下将球体聚合 煮^ 2-3小 时, 使其进一步聚合和硬化; 然后, 用热水洗涤, 在 50 C 温度下烘千, 再 用石油醚淋洗脱蜡, 获得三元共聚超大孔树脂;
将上迖树脂放入电阻炉中, 在惰气保护下, 在 100-300 C 的溫度下予烧 8-10小时, 然后升温至 500-800 °C, 再通入水蒸气活化 0.5-1.0 小时后冷却, 即获得碳化树脂;
( 2 ) 制备碳化树脂 DNA免疫吸附剂
把小牛胸腺 DNA 溶液与火棉胶乙醚溶液混合均匀后, 一边迅速搅拌, 一边 加入经过予处理的碳化树脂, 使液^艮快被吸千, 然后用 50-60 °C 的热水浴 恒温淋洗 2小时, 并不时搅拌, 至溶剂完全挥发, 再在 50fc温度下真空千燥 2 小时, 用水漂洗数遍后装入洗涤塔淋洗, 直到流出液在 260iim处无紫外吸 收, 然后再漂洗数遍, 在 50t真空下干燥, 即获得成品吸附剂。
采用本发明的方法制得的 DNA免疫吸附剂中 DNA的含量达 0.3-0.5mg/mi 树脂。
将按本发明制备的 DNA 免疫吸附剂装入特制吸附罐, 经消毒处理成为 医用血液灌流吸附装置。 血液从患者动脉中引出, 流经吸附装置, 患者血液 中的致病物质被 DNA 免疫吸附剂吸附, 洁净的血液从装置中流出, 由静脉 流回患者体内。 灌流治疗过程一般为 2-3 小时。 血液灌流与血液透析相似, 安全、 简便、 费用 氐。
下面, 详细描述本发明的方法。
1、 制备碳化树脂
将 5.0-7.5%w/w 苯乙烯, 10.0-12.5%w/w二乙烯笨, 7.5-10.0%w/w 丙烯 腈, 50.0%w/w 甲苯混合均匀, 加入 0.15-0.3%vv/w 引发剂过氧化苯甲酰, 溶 解后加入 25.0%w/w 液体石蜡, 充分混合均匀, 成为有机相, 致孔剂 (曱笨 和液体石蜡) 是单体总量的三倍。 在 3000ml 三口瓶中, 加入 2 倍于有机相 体积的 1-2%聚乙烯醇溶液, 水浴加热至 50^:。 将有机相加入到反应瓶中, 搅
替换页 (细则第 26糸)
拌, 升温至 80 ° (:, 反应 3-5小时。 升高水浴温度至 90-100 eC, 蒸榴甲笨。 在 100 °C下将球体聚合物煮沸 2小时, 过滤,' 用热蒸馏水洗涤树脂数遍。 50 *C 烘干, 用石油醚淋洗或加热提取, 除去致孔剂液体石蜡, 得到三元共聚超大 孔树脂。 用标准筛筛选 0.45-1.0mm合格树脂,
在管式电阻炉中加入大孔树脂, ' 100-300。C预烧 8-10 小时, 在 Νζ·.气保 护下, 以 100 tV小时的速度升温至 500-800 °C , 在此温度下通入蒸气, 活化 0.5-1 .0小时, 自然冷却至室温, 得到 0.45-0.9mm碳化树脂约 350mL
将得到的碳化树脂用 2倍体积的 5%盐酸煮沸 30分钟, 用二次蒸馏氷洗 至中性。 再用 2倍体积的 5%氢氧化钠煮沸 30分钟, 用二次蒸馏水淋洗至中 性。 50t烘千。 用热无水乙醇提取 24小时, '洪千备用。
2、 制备碳化树脂 DN A免疫吸附剂
( 1 ) DNA 溶液配制: 高纯度小牛胸腺 DNA 溶解于 0.2mol/l Tns- HCL(pH=7.4)緩沖溶液中, 浓度为 4mg/ml。 依次加入等体积氯化 四氮唑兰铯和水溶液和等体积无水乙醇, 搅拌或振荡至完全溶解。
( 2 ) 水棉胶配制: 5%火棉胶乙鲢溶液用无水乙醚稀释 7.4倍。
( 3 ) 包膜:
将 19-20%v/vDNA溶液与 21 .4-22.9v/v 火棉月交混合均匀, 在搅拌下倒入 57.1-59.5%v/v碳化树脂, 搅拌均匀, 液体被迅速吸干。 在 50-60 t热水浴上 恒溫 1 -2小时, 不时搅拌, 50 C真空干燥 2小时。 用高纯度注射用水漂洗和 淋洗, 至流出液在 260nm处的紫外吸收为 0.000。 50 eC真空干燥数小时, 即 得成品碳化树脂 DNA免疫吸附剂。
本发明制备的碳化树脂 DNA免疫吸附剂装入吸附罐中, 共 250ml, 密封 后消毒, 使用前用无菌生理盐水浸泡 30分钟以上, 再用 3000ml无菌生理盐 水冲洗。 在患者股动脉和臂静脉插.管, 灌流前 10-20 分钟静脉注入肝素 1- 1.5mg/kg 体重。 整个灌流系统保温 37 ° (:。 接通动静脉后开始灌流, 流速由 50ml/min 逐渐增力 σ至 200ml/nim。 于动脉端取血, 测定 DNA 抗体、 免疫复 合物及其它生化指标。
本发明采用新的工艺合成方法合成了性能优良的免疫吸附剂载体材料碳 化树脂, 首先采用超大量致孔剂 (致孔剂用量为单体和交联剂总量的三倍) , 严格控制引发剂用量和升温速度, 即严格控制聚合速度。 另外, 快速蒸馏出 致孔剂曱笨, 这样才能最终得到具有超大孔和大比表面积的树脂。 碳化过程 的预烧、 程序升温、 碳化温度和水蒸气活化至关重要, 直接影响和决定碳化 树脂的收率和结构性能, 本发明制备的碳化树脂具有适宜的孔径和比表面积 (孔径 20—35A , 比表面积 800-1200n^ml ) ,是制备 DNA免疫吸附剂的优良 栽体材料, 同时具有非常好的血液相容性, 对血小板、 红细胞和白细胞的破 坏率很低, 临床应用结杲也证明本发明碳化树脂的优越性能。
一 3一
替换页 (细则第 26条)
本发明制备的碳化树脂 DNA免疫吸附剂, 已在全国 17个城市 28 家医 院进行了 150多例临床应用, 有效率达 98%, 患者不仅延长了生命, 而且恢 复了健康和劳动能力。 表 1和表 2分别列举了部分 SLE临床报告。 如表 1所 示, 十名患者经血液灌流后, 血液中的致病物质抗 ds-DNA抗体的浓度明显 降低, 尿蛋白、 血沉和抗核抗体滴度:^明显改善。 除一人死亡外 (存活 38 个月) , 其余 9人已存活 32个月以上, 恢复了生活和劳动能力 另外如表 2 所示, 通迚对 5名 SLE患者进行多次血波灌流治疗发现, 患者血液生化指标、 临床症状越来越改善, 特别是患者经治疗后, 均停止服用任何激素类药物, 其中 4人目前已分别存活 9, 12, 24, 24 (随访日期至 1996年底) , 只有 1 人在存活一年后死于综合症。 这表明 DNA免疫吸附剂疗法不仅能緩解病情, 而且能改善患者的免疫系统功能, 保持长期疗效, 并有治愈的可能。 本发明的聂佳实施方式
实施例 1.
制备碳化树脂。
将 45.0g笨乙烯, 60.0g二乙烯笨, 45.0g丙烯腈, 300.0g曱笨混合均匀, 加入 1.5g引发剂过氧化苯甲酰,溶解后加入 160.0g液体石蜡, 分混合均匀。 在 3000ml三口瓶中, 加入 1%聚乙烯醇水溶液 1150mi, 氷浴加热至 50°C, 将 上迷单体溶液倒入反应瓶, 搅拌, 在 1小时内^^应液升温至 80 :, 反应 5 小时。 升高水浴温度至 90 °C 以上, 蒸 曱笨约 1 小时, 直到不再有甲笨蒸 出为止。 在 100 °C下将球体聚合物煮沸 2小时, 使其进一步聚合和硬化, 过 滤, 用热蒸憎水洗涤数遍, 除去聚乙烯醇。 50 C烘千, 用石油醚( 60-90 淋洗树脂, 除去致孔剂中的液体石蜂。 用标准筛筛选 0.45-1.0mm范围的合格 树脂, 约 400ml。
在管式电阻炉中加入 1000ml上 树脂, 200 eC预烧 10小时后, 在 N2气 保护下, 以 100 'C/小时的速度升溫至 800 t, 在此溫度下通入蒸气活化 1 小 时, 自然冷却至室温, 得到约 350ml 0.45-0.9mm的合格碳化树脂。 比表面积 为 1000-12000027 平均孔径20-35人。
制备碳化树脂 DNA免疫吸附剂。
取制得的碳化树脂 250ml, 用 2倍体积的 5%盐酸煮沸 30分钟, 用重蒸 水洗至中性。 再用 2倍体积的 5%氢氧化钠溶液煮沸 30分钟, 用重蒸水漂洗、 淋洗至中性。 50'C烘干。 在提取装置内用无水乙醇回流 24小时, 烘千备用。
所用溶液均用注射用水配制,使用纯化 DNA。在洁净无菌的环境下操作, 目的是保证产品无热源。
于 1000ml烧杯中加入 80ml小牛胸腺 DNA溶液( DNA溶解在 0.2MpH=7.4 的 Tris-HCL緩冲溶液中, 浓度为 4mg/ml, 然后依次加入等体积的氯化四氮
替换 ^ (细则第 26条)
唑兰饱和水溶液和无水乙醇, 搅拌至絮状^ 7完全溶解) , 90ml 火棉胶溶液 ( 55mI5%火棉胶的乙醚溶液,用 350ml无水乙 稀释 ) ,在搅拌下加入 250ml 上迷经过预处理的碳化树脂, 迅速搅拌均匀, 液体被很快吸千。 在 50-60 ¾ 热水浴上, 恒温 2小时, 不时搅拌, 至溶剂完全挥发。 50'C真空干燥 2小时。 用注射用水漂洗数遍, 装入淋洗塔琳 '洗, 直到流出液在 260nm处无紫外吸收。 再漂洗数遍, 50 °C真空千燥, 得到成品吸附剂。 DNA含量为 0.38m /mi树 脂。 用兔子进行热源实验, 产品无热源。
实施例 2 '
本实施例在实施倒 1 的制备碳化树脂的过程中, 将在管式电阻炉中的碳 化溫度改为升温至 580 °C, 结杲, 所得到的碳化树脂的比表面 ^仅为 100m /g 左右。 其余步骤均与实施例 1 相同。 从这一参数的变化可知, 所制得的成品 吸附剂中的 DNA含量将大大减少。
实施例 3
在实施例 1 的制备碳化树脂的过程中, 将制备碳化树脂过程中的水蒸汽 活化时间改变为 0.5 小时。 结杲, 所得到的碳化树脂的比表面积略有减少, 为 800-1000m2 /g。 其余步骤均与实施例 1相同。 由此可推断, 成品吸附剂中 的 DNA含量也将相应减少
实施例 ·
在实施例 1 的制备碳化树脂的过程中, 在将树脂加入管式电阻炉后, 不 经过 200 "C预烧 10小时的步骤, 直接在 ^气保护下升温至 800 t:。 结杲, 碳化树脂的收得率很低, 同样的投料量, 仅收得不足 200ml 的碳化树脂。 可 见预烧步驟可大大提高产品的收得率。
实施例 5
在本实施例是在实施例 1 的制备碳化树脂 DNA免疫吸附剂的过程中, 将小牛胸腺 DNA 溶液的投料量改为 87.5ml , 火棉交溶液的投料量改为 100ml, 碳化树脂的投料量改为 250ml。 其余条件与实施例 1相同。 结果, 成 品吸附剂中的 DNA含量提高到 0.42mg/ml树脂。
实施例 6
在实施例 1 的制备碳化树脂 DNA免疫吸附剂的过程中, 工艺条件完全 相同, 只是漂洗和淋洗的水不使用注射用水, 而全部使用重蒸水。 结杲, 用 兔子对所得的成品吸附剂进行实验, 发现有明显热源反应, 说明产品中存在 热源物质。 可见, 使用注射用水对于避免和消除热源物质有决定性作用。 工业应用性
本发明的制备碳化树脂 DNA 免疫吸附剂的方法改进了碳化树脂包膜固 定 DNA的包膜奈件, 提高了吸附剂的吸附性能, 并且在制备过程中避免和 替换页(细则第 26条)
消除了热源物质, 从而能制成吸附效率更高, 更加符合临床医用要求的 DNA 免疫吸附剂。 此外, 本发明的方法由亍原料容易获得, 工艺合理, 还能大大 降低吸附剂的制造成本。
替换页(细则第 26条)
)
10例 SLE病例报告总结 (随访至 1998年 2月) 基本情况 检验结果 (灌流前 /灌流后 1周)
编 吸附
转归 号 免疫球蛋 抗核抗 抗 ds-DNA 次数
性别 年龄 发病时间 治疗时间 尿蛋白 血沉 补体 c3
白 (g L) 体滴度 抗体
存活 44个月,
1 女 23 1992,1 1994,6 ++/- 42/13 13.6/ 1280/240 0.42/1.23 34.8/16.2 2
恢复原工作 存活 38个月,
2 女 34 1993,7 1994,7 +++/+ 38/12 18.6/14.3 800/80 0.31/0.81 36.5/16.0 2
死于败血症 存活 40个月,
3 女 31 1994,4 1994,10 ++/- 58/14 19.3/14.1 1040/160 0.40/1.22 34.3/16.3 2
从事家务 存活 39个月,
4 女 29 1992,11 1994,11 ++/- 40/16 14.4/ 160/ 0.51/1.31 18.0/ 2
从事家务 存活 35个月,
5 男 31 1994,7 1995,3 ++/- 55/18 21.3/12.6 880/160 0.43/1.24 17.5/ 2
6 男 32 1992,3 1995,3 +++/+ 43/16 19.3/11.4 1280/240 0.32/1.67 28.5/14.1 2
从事家务 存活 35个月,
7 女 33 1994,11 1995,3 +/- 65/16 12.5/ 1280/240 0.81/ 33.4/14.5 1
恢复原工作 存活 34个月,
8 女 41 1991,4 1995,4 +++/- 78/18 18.6/10.5 80/ 0.83/ 31.1/16.6 2
生活自理 存活 33个月,
9 男 24 1995,3 1995,5 ++/- 66/14 20.2/13.2 1200/160 0.54/1.21 33.8/15.5 2
恢复车间工作 存活 32个月,
10 女 26 1995,1 1995,6 +/- 52/16 19.2/12.7 1040/80 0.86/ 36.8/15.7 1
从事饮食业
表 2. 例 SLE病例报告总结 (随访至 1996年底)
Claims
权利要求'
1、 一种 DNA免疫吸附剂的制备方法, 它使 碳化树脂作为载体, 在其上固 定了有效量的 DNA, DNA的含量 Q.3-0.5mg/ml树脂, 其特征在于, 该方 法包括下列步骤:
( 3 ) 制备碳化树脂
以笨乙烯和丙烯腈为单体, 以二乙烯笨为交联剂, 以三倍于单体和交联 剂 (重量比) 的曱笨和液体 ^蜡为致孔剂, 以过氧化苯曱酰为引发剂, 以 1- 2%聚乙烯醇水溶液为分教介质, 进行悬浮聚合, 在 S0 °C 温度下反应 5小时; 然后, 在 96 t温度下蒸馏甲笨, 再在 100 eC温度下将球体聚合物煮沸 2-3小 时, 使其进一步聚合和硬化; 然后, 用热水洗涤, 在 50 eC 温度下烘干, 再 用石油醚淋洗脱碏 , 获得三元共聚超大孔树脂;
将上述树脂放入电阻炉中, 在惰气保护下, 在 100-300 eC 的温度下予烧 8-10小时, 然后升温至 500-800 eC, 再通入水蒸气活化 0.5-1.0小时后冷却, 即获得碳化树脂;
( ) 制备碳化树脂 DNA免疫'疆剂
把小牛胸腺 DNA溶液与火撺^ L乙瞇溶液混合均匀后, 一边迅速搅拌, 一边 加入经迚予处理的碳化树脂, 使液体很快被吸千, 然后用 50-60 的热水浴 恒温淋洗 2小^, 并不时搅拌, 至溶射完全揮发, 再在 50° (:温度下真空干燥 2 '〗、时, 用水漂洗数 ^洗条塔林' 直到流 液在 260nm处无紫外吸 收, 然后再漂洗数遍, 在 50t真空下干燥, ^"获得成品吸附剂。
2、 如权利要求 1所迷的 DNA免疫吸 ^剂的制备方法, 其特征在于, 各种物 料的配比为:
( 1 ) 制备碳化树脂过程中: 有; 目由单体笨乙烯 5.0-7.5%w/w, 丙烯腈 7.5-10.0%w/w,交联剂二乙烯苯 10.0-12.5%w/w,致孔剂 甲笨 50.0%w/w,液体石蜡 25.0%w/w 和引发剂过氧化笨甲酰 0.15- 0.3%w/w组成, 引发剂过氧化苯曱酰为笨乙烯和二乙烯苯总量的 0.5-1.0%, 水相为 1-2%聚乙烯醇溶液,有机相与水相的重量比为 1 : 2;
( 2 ) 制备免疫吸附剂过程中: 碳化树脂 57.1-59.5%v/v,DNA 溶液 19- 20%v/v,火棉胶乙醚溶液 21.4-22.9%v/v, DNA浓度为 1.33mg ml, 火 棉胶浓度为 0.68%,
——
替换页(细则第 26条)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0002399A GB2343511A (en) | 1998-06-08 | 1999-06-07 | A method for preparing a carbonized resin DNA immunoadsorbent |
JP2000553139A JP2002517471A (ja) | 1998-06-08 | 1999-06-07 | 炭化樹脂dna免疫吸着剤の製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98102355A CN1209548A (zh) | 1998-06-08 | 1998-06-08 | 碳化树脂dna免疫吸附剂的制备方法 |
CN98102355.X | 1998-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999064071A1 true WO1999064071A1 (fr) | 1999-12-16 |
Family
ID=5217286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN1999/000076 WO1999064071A1 (fr) | 1998-06-08 | 1999-06-07 | Procede de preparation d'un immunoadsorbant adn dans une resine carbonisee |
Country Status (5)
Country | Link |
---|---|
US (1) | US6262172B1 (zh) |
JP (1) | JP2002517471A (zh) |
CN (1) | CN1209548A (zh) |
GB (1) | GB2343511A (zh) |
WO (1) | WO1999064071A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10149251B4 (de) * | 2001-10-05 | 2007-04-19 | Sartorius Ag | Vorrichtung zur genetischen Immunisierung durch Einbringen von Wirkstoffen in ein Gewebe und Verfahren zur Herstellung einer Injektionslösung |
CN101033248B (zh) * | 2006-03-10 | 2011-08-17 | 周逸明 | 一种制备小牛胸腺alpha1的新工艺 |
CN105032373B (zh) * | 2015-05-29 | 2017-11-24 | 珠海健帆生物科技股份有限公司 | 一种具有仿生包膜材料的吸附剂及其制备方法 |
CN106994336A (zh) * | 2016-01-25 | 2017-08-01 | 于杰 | 适用于精准血液净化疗法的医用吸附树脂 |
CN105126784B (zh) * | 2015-07-31 | 2018-01-02 | 珠海健帆生物科技股份有限公司 | 吸附剂及其制备方法、用于血液灌流的吸附装置 |
CN105289538A (zh) * | 2015-11-04 | 2016-02-03 | 珠海健帆生物科技股份有限公司 | Dna免疫吸附剂及其制备方法 |
CN108246264B (zh) * | 2016-12-28 | 2020-12-15 | 健帆生物科技集团股份有限公司 | 一种dna免疫吸附剂及其制备方法 |
CN106622173A (zh) * | 2016-12-29 | 2017-05-10 | 珠海健帆生物科技股份有限公司 | Dna免疫吸附剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0054799A2 (en) * | 1980-12-18 | 1982-06-30 | Asahi Kasei Kogyo Kabushiki Kaisha | A dried, sterilized, gamma-globulin-fixed column and a process for preparing the same |
EP0118256A2 (en) * | 1983-03-04 | 1984-09-12 | Scripps Clinic And Research Foundation | Immunoadsorbent, and method of recovering vitamin-K dependent protein therewith |
EP0237659A1 (en) * | 1985-01-11 | 1987-09-23 | Imre Corporation | Process for the production of Protein a-silica immunoadsorbent |
EP0272792A1 (en) * | 1986-11-21 | 1988-06-29 | Imre Corporation | Antigen-specific removal of circulating immune complexes |
-
1998
- 1998-06-08 CN CN98102355A patent/CN1209548A/zh active Pending
-
1999
- 1999-06-07 GB GB0002399A patent/GB2343511A/en not_active Withdrawn
- 1999-06-07 WO PCT/CN1999/000076 patent/WO1999064071A1/zh active Application Filing
- 1999-06-07 JP JP2000553139A patent/JP2002517471A/ja active Pending
-
2000
- 2000-02-07 US US09/499,312 patent/US6262172B1/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0054799A2 (en) * | 1980-12-18 | 1982-06-30 | Asahi Kasei Kogyo Kabushiki Kaisha | A dried, sterilized, gamma-globulin-fixed column and a process for preparing the same |
EP0118256A2 (en) * | 1983-03-04 | 1984-09-12 | Scripps Clinic And Research Foundation | Immunoadsorbent, and method of recovering vitamin-K dependent protein therewith |
EP0237659A1 (en) * | 1985-01-11 | 1987-09-23 | Imre Corporation | Process for the production of Protein a-silica immunoadsorbent |
EP0272792A1 (en) * | 1986-11-21 | 1988-06-29 | Imre Corporation | Antigen-specific removal of circulating immune complexes |
Also Published As
Publication number | Publication date |
---|---|
US6262172B1 (en) | 2001-07-17 |
CN1209548A (zh) | 1999-03-03 |
JP2002517471A (ja) | 2002-06-18 |
GB2343511A (en) | 2000-05-10 |
GB0002399D0 (en) | 2000-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100348268C (zh) | 碳化树脂dna免疫吸附剂的制备方法 | |
US5403917A (en) | Process for the quantitative selective removal or preparative isolation of tumour necrosis factor (TNF) or/and lipopolysaccharides (LPS) from aqueous liquids | |
US5679775A (en) | Process and device for the simultaneous extracorporeal elimination of tumour necrosis factor and bacterial lipopolysaccharides from whole blood and/or blood plasma | |
CN104174385B (zh) | 一种用于血液灌流的胆红素吸附剂 | |
CN102091595B (zh) | 对低密度脂蛋白有特异性吸附的球状炭气凝胶的制备方法 | |
US11759561B2 (en) | Therapeutic compositions for viral-associated disease states and methods of making and using same | |
JPH0365190B2 (zh) | ||
CN104174386B (zh) | 一种用于清除血液中beta-2微球蛋白的吸附剂 | |
EA002896B1 (ru) | Метод удаления бета-2 микроглобулина из крови | |
JP2023130402A (ja) | 内毒素血症誘発分子を除去するための血液適合性多孔質ポリマービーズ収着材の使用 | |
CN106268703A (zh) | Dna免疫吸附剂及其制备方法 | |
WO1999064071A1 (fr) | Procede de preparation d'un immunoadsorbant adn dans une resine carbonisee | |
Zong et al. | Preparation of PVA/amino multi-walled carbon nanotubes nanocomposite microspheres for endotoxin adsorption | |
CN106238023B (zh) | 一种用于改善血液净化材料表面生物相容性的包膜方法 | |
CN113509919B (zh) | 一种可用于清除脓毒症患者血液中内毒素和炎症因子的吸附剂及其制备方法 | |
US20200197598A1 (en) | Therapeutic Compositions for Viral-Associated Disease States and Methods of Making and Using Same | |
CN110975842A (zh) | 免疫吸附剂及其制备方法、用于血液灌流的吸附器 | |
Xu et al. | Studies of adsorbents for hemoperfusion in artificial liver support. I. Preparation and in vitro studies of cross-linked agarose beads entrapped activated charcoal (CAAC) | |
JPH0518625B2 (zh) | ||
CN104525153A (zh) | 一种用于ldl清除的吸附剂及其制备方法 | |
RU2366958C2 (ru) | Способ очистки крови от антител к тиреоидным гормонам с помощью иммобилизированного гранулированного магнитоуправляемого препарата | |
JP2853452B2 (ja) | 生理活性物質固定化成形品の製造方法 | |
CN114426653B (zh) | 一种用于吸附β2-MG的树脂的制备方法及应用 | |
JP2014135976A (ja) | 塩基性線維芽細胞増殖因子の吸着材とその利用 | |
US11918728B2 (en) | Therapeutic compositions for viral-associated disease states and methods of making and using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99800883.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN DE GB JP US |
|
WWE | Wipo information: entry into national phase |
Ref document number: GB0002399.4 Country of ref document: GB |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |